EGFR and non-small cell lung carcinoma: Therefore, it received accelerated FDA approval in May 2021 for patients with NSCLC with EGFR exon 20 insertions who progressed on or after platinum-based chemotherapy (www.fda.gov accessed on 14 May 2023).